| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Marjorie B. Kovler Viral Oncology Laboratories, The University of Chicago, 910 East 58th Street, Chicago, Illinois 60637
Received 13 September 2007/ Accepted 5 February 2008
Earlier studies have shown that in herpes simplex virus 1-infected cells, ICP22 upregulates the accumulation of a subset of
2 proteins exemplified by the products of the UL38, UL41, and US11 genes. The ICP22-dependent process involves degradation of cyclins A and B1, the stabilization and activation of cdc2, physical interaction of activated cdc2 with the UL42 DNA synthesis processivity factor, and recruitment and phosphorylation of topoisomerase II
by the cdc2/UL42 complex. Activation of cdc2, the first step in the process, is a key function of the mitotic phosphatase cdc25C. To define the role of cdc25C, we probed some features of the ICP22-dependent pathway of upregulation of
2 genes in cdc25C–/– cells and in cdc25C+/+ cells derived from sibling mice. We report that cyclin B1 turned over in cdc25C+/+ or cdc25C–/– cells at the same rate, that cdc2 increased in amount, and that US11 and UL38 proteins and infectious virus accumulated in smaller amounts than in wild-type infected cells. The reduction in UL38 protein accumulation and virus was greater in cdc25C–/– cells infected with virus lacking ICP22 than in cells infected with wild-type virus. We conclude that cdc25C phosphatase plays a role in viral replication and that this role extends beyond its function of activating cdc2 for initiation of the ICP22-dependent cascade for upregulation of
2 gene expression.
Published ahead of print on 13 February 2008.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|